Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Trial Profile

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms C-TASK FORCE
  • Most Recent Events

    • 28 Jul 2017 Primary endpoint (4 month progression free survival by central assessment) has been met, as per results published in the Lancet Oncology.
    • 28 Jul 2017 Results published in the Lancet Oncology
    • 07 Aug 2015 Status changed from active, no longer recruiting to completed as per University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top